



UNIVERSITY OF LEEDS

This is a repository copy of *Novel artificial eye service evaluation using patient reported outcome measures*.

White Rose Research Online URL for this paper:
<https://eprints.whiterose.ac.uk/167800/>

Version: Accepted Version

Article:

Gout, T, Walshaw, EG, Zoltie, T orcid.org/0000-0003-3411-341X et al. (7 more authors) (2021) Novel artificial eye service evaluation using patient reported outcome measures. *Eye*, 35 (7). pp. 2030-2037. ISSN 0950-222X

<https://doi.org/10.1038/s41433-020-01216-z>

© The Author(s), under exclusive licence to The Royal College of Ophthalmologists 2020. This is an author produced version of an article published in *Eye*. Uploaded in accordance with the publisher's self-archiving policy.

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

Title Page

Title: Novel artificial eye service evaluation using patient reported outcome measures

Running Title: Novel artificial eye service evaluation

Authors:

Taras Gout, Oculoplastics Fellow, Department of Ophthalmology, Leeds Teaching Hospitals NHS Trust. 0113 243 3144. tarasgout@gmail.com. (corresponding author).

Emma Grace Walshaw, Middle Grade Oral and Maxillofacial Surgery, Department of Maxillofacial Surgery, Leeds Teaching Hospitals NHS Trust. 0113 243 3144.

Timothy Zoltie, Head of Medical and Dental Illustration, Department of Medical and Dental Illustration, University of Leeds. 0113 243 3144.

Paul Bartlett, Chief Maxillofacial Prosthetist, Maxillofacial Laboratory, Leeds Teaching Hospitals NHS Trust. 0113 243 3144.

Tom Archer, Medical and Dental Illustrationist, Department of Medical and Dental Illustration, Leeds Teaching Hospitals NHS Trust. 0113 243 3144.

Asmaa Altaie, Clinical Lecturer/Honorary Speciality Registrar in Restorative Dentistry, School of Dentistry, University of Leeds. 0113 243 3144.

Jiten Parmar, Consultant Oral and Maxillofacial Surgery, Department of Maxillofacial Surgery, Leeds Teaching Hospitals NHS Trust. 0113 243 3144.

Nabil El-Hindy, Consultant Ophthalmology. Department of Ophthalmology, Leeds Teaching Hospitals NHS Trust. 0113 243 3144.

Bernie Chang, Consultant Ophthalmology. Department of Ophthalmology, Leeds Teaching Hospitals NHS Trust. 0113 243 3144.

George Kalantzis, Consultant Ophthalmology. Department of Ophthalmology, Leeds Teaching Hospitals NHS Trust. 0113 243 3144.

All authors meet the standards required to be contributing authors for this article. There are no conflicts of interest to declare.

Abstract

Background: This service evaluation explores patient reported outcomes from patients provided with high definition ocular prostheses (artificial eyes).

Methods: Validated patient questionnaires (FACE-Q, DAS24 and HADS) were utilised to evaluate patient experiences of their new ocular prosthesis. 10 patients were included in the service evaluation, which was conducted between December 2018 and September 2019. Descriptive analysis of the mean and 95% CI was undertaken for all questionnaires. Statistical analysis was performed using SPSS 21 Principal Component Analysis (PCA) for FACE-Q questionnaires. Correlations were significant when factor loading is at $\alpha > 0.4$.

Results: A questionnaire response rate of 80% was achieved (n=8). PCA analysis showed the number of variables tested could be reduced. Two principal components (PC1 and PC2) had very good to excellent internal consistency between variables with factor loading ($\alpha = 0.7-0.9$). PC1 contained questionnaires 1-7, all of which were highly correlated. PC2 contained question number 8 with a factor loading of $\alpha = 0.8$. This indicates good reliability, validity and responsiveness.

Conclusion: We hope to demonstrate the importance of service evaluations with respect to rapidly evolving technological advances in medical devices, pharmaceuticals and imaging modalities. Further feasibility and full clinical studies are required to confirm the positive results of the novel artificial eye service we have evaluated with respect to the traditional approach.

Introduction

Healthcare technology advances have reduced mortality and morbidity, increased longevity and improved quality of life for people worldwide. However, this has also resulted in ever increasing healthcare costs both as an absolute value and as a percentage of GDP since the inception of the National Health Service in the UK ¹. Service evaluations are increasingly used to address key stakeholder requirements, informing funding provisions, and guide local and national service provision models.

Within ophthalmology the landscape of service provision has greatly changed due to technological advances as seen by the setting up of intravitreal injection clinics, glaucoma monitoring units, and diabetic retinopathy screening services. This rapidly changing world of clinical practice due to technological advances has resulted in service evaluations becoming a vital part of the armamentarium in the clinical governance toolkit.

Novel medical devices, imaging modalities and pharmaceuticals are rapidly expanding and accounting for ever increasing quality of healthcare delivery as well as percentage of healthcare budgets.

Procurement justification for novel medical devices is becoming increasingly focused on value rather than price alone, which has made Patient Reported Outcome Measures (PROMs) more widely used in their evaluation ². In the UK, 65% (121 out of 186) of novel medical device studies between 1998 and 2018 included PROMs ². While in the US, there has been over a 500% increase in the utilisation of PROMs in medical device trials between 2009 and 2015 ³.

The primary aim of this paper was to demonstrate the importance of service evaluations in the refinement of a new service. The example we provided is of novel artificial eye service, which can provide life-like artificial eyes within a short manufacturing timeframe. Our aim is to improve the initial rehabilitation pathway and long-term quality of life of artificial eye patients. Therefore, the outcome measures used are based on quality of life.

Service evaluations and clinical audits are both placed in the sphere of clinical governance. Clinical audits tend to evaluate specific clinical outcomes of a service with a focus on clinical outcomes. Whilst service evaluations tend to have broader aims of addressing key stakeholder requirements, informing funding provisions, and guiding larger structural changes to service provision.

Artificial Eyes

Patients may require surgery to remove a blind painful eye following trauma, cancers or congenital conditions. The operations carried out include eviscerations, enucleations and orbital exenterations. Following healing of the surgical area the subsequent rehabilitation involves fitting an artificial eye. Patients with ocular prostheses report a reduced quality of life and increased prevalence of depression and anxiety ^{4,5}. In 2006, Song et al reported that patients

who felt their artificial eye was imperceptible to others had higher patient satisfaction rates, irrespective of the surgery performed or implant provided ⁶. Despite this knowledge, there has been limited research into the scope for improvement in appearance of ocular prostheses.

Following clinical observations and patient testimonials, there was clearly a high level of unmet patient need and demand for improvements in ocular prostheses within our local area. This stimulated the development of a novel technique for fabricating ocular prostheses by Maxillofacial prosthetists and medical illustrationists in Leeds Teaching Hospitals NHS Trust. This new manufacturing technique allows digital photography of the patient's unaffected eye to produce high definition prostheses in a short time frame with increased patient personalisation ⁷.

Our Service

The production of our new technique began development within LTHT over 10 years ago, and has anecdotally been met with great praise from patients. All patients were originally recruited into the service following the provision of a National Artificial Eye Service (NAES) prosthesis. NAES are currently the national providers of ocular prostheses to National Health Service (NHS) users. Although there are over thirty other artificial eye service providers nationally, mainly within maxillofacial prosthetics laboratories.

On referral to the LTHT service the maxillofacial prosthetist (PB) and medical photographers (TZ, TA) spend time with the patient designing their prosthesis and taking necessary digital photographs. Once fabricated, the prosthesis is fitted and minor adjustments made to suit patient's preference if required ⁷. There is future scope for this process to be undertaken within one clinical session, however at present this is spread over the course of a week due to non-clinical logistical pressures. Figure 1 demonstrates the current patient journey through this high definition ocular prosthetic service.

Figure 1

The scope of this paper is to demonstrate formalised quality of life responses using validated questionnaires from patients utilising this new service. This information will support service improvement by identifying areas of potential development.

Methods

Our service evaluation was undertaken at Leeds Teaching Hospitals NHS Trust in Leeds Dental Institute. The Trust Research and Innovation Centre supported and approved the service evaluation. A sample size of ten adult patients (over 18 years old) was selected to capture a representative cross-section of services users on a convenience basis. This evaluation was

performed over a nine month timescale (December 2018 to September 2019) and covered the complete patient pathway from initial visit, to manufacture of prosthesis, and finally patient questionnaires. A response rate of 80% (n=8) was achieved.

Patients were evaluated via telephone conversations or letter responses, as per their personal preference. The majority (n=7) opted for telephone conversations considering their visual impairment, often affecting their remaining biological eye and causing difficulty in reading a written questionnaire with ease. The option for either phone or letter responses was highlighted as very important by patients during a previous Patient and Public Involvement (PPI) initiative regarding this new service. This PPI allowed patients the freedom to express their thoughts about the service directly to those involved in its development.

Our choice of patient reported outcome measure (PROM) was based on literature review and online database searches; FACE-Q (FACE-Q © 2013), DAS24 (Derriford Appearance Scale 24) and HADS (Hospital Anxiety and Depression Scale) were selected⁸⁻¹⁰. Literature review of PROMs specifically in relation to artificial eyes is scarce. However, there are many well validated PROMs for anxiety, depression, social interaction and appearance which can be applied to those who have lost an eye and require prosthetic replacement^{10,11}. In itself this creates a challenge in balancing between questionnaire validity and applicability.

FACE-Q patient reported outcome instrument was assessed and eight individual questionnaires were selected based on clinical relevance: (1) Psychological function, (2) Satisfaction with eyes, (3) Adverse effects: Eyes, (4) Satisfaction with outcome, (5) Appearance-related psychological distress, (6) Social Function, (7) Satisfaction with facial appearance, (8) Expectations. Development of the FACE-Q instrument was well constructed resulting in reliable, valid and responsive measures¹²⁻¹⁵. Participants would be asked to state how much they agree or disagree with statements such as “I feel positive about myself” and “I feel confident” in the Psychological Function questionnaire. Scoring system is standardised with a range of 1-4 and higher scores reflecting a better outcome. A Conversion Table transforms the raw scale summed score into an equivalent Rasch transformed score from 0 (worst) to 100 (best).

DAS24 (Derriford Appearance Scale) is an instrument designed to measure adjustment to problems of visible difference and disfigurement⁸. The initial open scoping questions are followed by those with psychometric scales for measuring distress and dysfunction. Participants are asked questions such as “How distressed do you get by shopping in department stores/supermarkets?” and “How distressed do you get when other people make remarks about your feature?”. The total score ranges from 11-96. Higher scores represent greater levels of social anxiety and social avoidance.

HADS (Hospital Anxiety and Depression Scale) is a well-established validated scale with almost forty years of application to a broad variety of medical and surgical specialties⁹. It was developed to evaluate patients with physical health problems. Being a relatively straightforward and quick scale to complete helps ensure maximal respondent attention. The fourteen items are divided evenly between anxiety and depression subgroups. Participants are asked to answer questions such as “I still enjoy the things I used to enjoy” and “I feel restless as if I have to be on

the move". Cumulative scores for each subgroup range from 0-21 and higher scores indicate greater levels of anxiety or depression. Scores of 0-7 are in the "normal" range; 8-10 suggests borderline abnormal levels of depression or anxiety; 11-21 is strongly suggestive of clinical depression or clinical anxiety.

Although these measures were specifically designed for clinical trial evaluations with strong foundations in their development, the binary patient acceptability of the service was seen as a simple yet highly effective way to gauge patient preference and impact of the service.

Descriptive analysis of the Mean and 95% Confidence Interval (CI) was undertaken for all questionnaires. Statistical analysis was performed using SPSS v.21 (SPSS Inc, Chicago, Illinois). Principal Component Analysis considered significant correlation at factor loading $\alpha > 0.4$. PCA was undertaken only on the comparable FACE-Q questionnaires due to the measures having good reliability, validity and responsiveness.

Results

Descriptive statistics

FACE-Q

The FACE-Q instruments' equivalent Rasch transformed score Means and 95% Confidence Intervals are discussed below and detailed in Table 1.

The lowest scoring instrument suggesting highest levels of distress was for Adverse Effects: Eyes scoring at 36.6(CI:27.5,45.7) and asking whether participants were bothered by: "How your eyelid scars look?", "Your eyes look hollowed out?", and "Eye irritation?". Appearance-Related Psychological Distress instrument also scored low at 37.4(CI:13.1,61.7) and assessed areas such as "I feel stressed with how I look" and "I tend to avoid being around people".

The highest scoring instrument suggesting least distress was for Satisfaction with Outcome at 63.7(CI:47.5,80.0) including questions such as: "I am pleased with the result" and "I am surprised at how good I look in the mirror". Expectations questionnaire also scored high at 61.8(CI:51.8,71.9) and covered areas such as "People will tell me how great I look" and "I will feel like I fit in."

A broad comparison to Klassen et al evaluation of FACE-Q questionnaires for patients undergoing cosmetic eye surgery is a good starting point, as there is currently no validated normative data for this qualitative tool with respect to artificial eye patients¹⁵. The following instruments had similar scores. Psychological Function 54.7(CI:32.6,76.9) and Social Function 54(CI:38.4,69.6) fell just below Klassen's rounded up range of 60-90 for both questionnaires. While appearance related instruments of Satisfaction - Eyes 59(CI:38.7,79.3) and Satisfaction - Facial Appearance 53.6(CI:39.7,67.4) were within Klassen's rounded up range of 50-80 and 50-70, respectively.

Table 1 demonstrates the FACE-Q instruments descriptive statistics.

Table 1

DAS24

DAS24 Total Score Mean and 95% Confidence Interval is 41.7(CI:24.6,58.7). There was an outlier with a total score of 91/96, which may have impacted the overall result. The 95% CI is broad indicating requirement for a larger data set in future studies. McBain and colleagues report a mean of 37.5 in a similar patient population of artificial eye users ⁵. Questions contributing the most to the total score were “I am self-conscious of my feature”, “How confident do you feel”, and “How distressed do you get when other people make remarks about your feature?”.

Table 2a-b shows the DAS24 Total and Individual Question descriptive statistics.

Table 2a-b

HADS

HADS Total Anxiety Score Mean and 95% Confidence Interval is 6.14(CI:2.5,9.7). According to the HADS classification of the total score the mean falls within the normal category (0-7). In a similar study population of artificial eye users, McBain et al report a slightly higher mean score at 6.9 in their study ⁵. In our study population the questions contributing the most to the anxiety total score were “I feel tense or wound up” and “I can sit at ease and feel relaxed”.

HADS Total Depression Score Mean and 95% Confidence Interval is 6.28(CI:1.9,10.6). The HADS classification of the total score is the same as for anxiety scale. The mean falls within the normal category. McBain et al reported a higher mean score of 7.6 ⁵. We found the questions contributing the most to the total score were “I still enjoy the things I used to enjoy” and “I feel as if I am slowed down”.

Table 3a-d demonstrates the HADS Total Score and Individual Questions descriptive statistics.

Table 3a-d

Binary Acceptability

Binary patient acceptability of the new service was 100% (8/8).

Figure 2

Principal Component Analysis

PCA is an analytical statistical method of data reduction. As a dimension reduction tool it identifies the correlation between the variables (questionnaires) tested and assesses whether it is possible to reduce the number of variables while maintaining data variance. Correlations were significant when factor loading is at $\alpha > 0.4$. The minimum number of variables is reached when their sum total accounts for $\geq 80\%$ variance.

PCA analysis showed two main components extracted accounted for 84% of the total variance. Thereby two dimensions in the component space account for 84% of the variance.

The first seven questionnaires laid into one component (PC1) which accounted for 70% of the total data variance. The second component analysis (PC2) contained question number 8 (FACE-Q Expectations) which accounted to 14% of the data variance. Therefore it was concluded that the number of variables can be reduced to 2 to include any of the variables in PC1 in addition to PC2. Table (1) shows the component matrix and the factor loading for each variable. PC1 contained questionnaires numbered (1-7) all of which were highly correlated with very good to excellent internal consistency with factor loading ($\alpha = 0.7-0.9$). PC2 contained question number 8 with a factor loading of ($\alpha = 0.8$).

Table 4 shows the FACE-Q Principal Component Analysis.

Table 4

Discussion

The evolution of orbital prostheses from the traditional hand-painted design has been explored by previous research teams^{16,17}, and usually published via single patient case reports. However, there is no evidence in the literature regarding the utilisation of digital photography and high-definition printing to identically replicate a patient's unaffected eye. Our technique is currently used with patients who already have an ocular prosthesis, provided by a different service (NAES).

Comparative bias may have arisen within patient responses, despite our efforts to minimise this by encouraging patients to evaluate the new prosthesis solely on its own merits. Future research should look at patient reported outcome measures for patients who have never had a prosthesis before.

Reportable outcome measures from family, friends and clinicians of patients could prove useful. Family and friends have been shown to notice different aspects of the prostheses from our previous PPI experience. Some patients with an ocular prosthesis have poor visual function in their remaining eye, and therefore find it difficult to judge the appearance of a prosthesis. In these cases, those close to the patient are a valuable source of opinion.

The sample size for this evaluation was limited. This number may have reduced the range of responses that could have been received, and so there is scope for missing patient opinions and the identification of potential strengths and weaknesses of the service. However, at this time the evaluation team felt the sample size would provide an indicative representation of the current service. We plan a larger scale review of the service at a later date.

There is no specific patient reported outcome measure for use with patients who have an orbital prosthesis. We have therefore used a large number measures for a thorough preliminary service evaluation. However, patient fatigue and resultant degradation of data quality may occur when patients are required to complete excessive numbers of questionnaires. We have therefore used a statistical tool, Principle Component Analysis (PCA), in order to select a few high-yield questionnaires based on their data variance. Subsequent service evaluations that we will undertake will only use 2 out of the 8 FACE-Q questionnaires that we used for our initial evaluation. This should reduce patient fatigue, improve data quality and streamline the subsequent service evaluation. We would recommend PCA for refining service evaluations when there are no specific patient reported outcome measures.

Service evaluations are within the remit of clinical governance and not research. As a result they can provide broad although still valuable results to guide service provision decisions. However, they are not designed to evaluate potential confounding features such as depression, anxiety and reason for surgery with respect to patient reported outcome measure results. A feasibility study followed by a full clinical trial, within the sphere of research, would be able to compare and contrast the traditional artificial eye to the new high-definition artificial eye. This step-wise approach would allow for evaluation of the patient reported outcomes in the feasibility study, as there no specific outcomes for artificial eyes. And thereby allow a better understanding, evaluation and minimisation of potential sources of bias in the full study. We plan to further evaluate the novel high-definition artificial eye with this approach.

The results of this service evaluation will be disseminated to key stakeholders within the provision of orbital prosthesis within our region and also nationally, in the hope of making substantial changes and informing funding provisions¹⁸. This aligns with the primary goal of evaluations in engaging stakeholders as active participants in the process and that the findings will be meaningful and useful to those ultimately responsible for assessing and improving the service. Regarding this service the key stakeholders involved are the participants (patients), active respondents such as local Eye Clinic Liaison Officers (ECLO) and Royal National Institute of Blind People (RNIB), consultants such as National Artificial Eye Service (NAES) and Specialist Commissioning Services Group representation, and the clinical team caring for the patients – Oculoplastic Surgery, Medical Imaging, Maxillofacial Prosthesis and Maxillofacial Surgery departments.

Conclusion

We hope to demonstrate the importance of service evaluations with respect to rapidly evolving technological advances in medical devices, pharmaceuticals and imaging modalities. Procurement justification for novel medical devices is becoming increasingly focused on value rather than price alone, which has made Patient Reported Outcome Measures (PROMs) more widely used in their evaluation. This is becoming especially important with increasing technological advances that need to be balanced against rising healthcare costs. Further feasibility and full clinical studies are required to confirm the positive results of the novel artificial eye service we have evaluated with respect to the traditional approach.

Acknowledgements

We would like to thank all patients who took part in this evaluation.

Conflict of Interests

There are no conflicts of interest to declare.

Funding

There are no external funding sources to declare.

References

1. NHS Expenditure by Rachael Harker. Documents NHS expenditure since 1948; summary of the structure of the NHS and how it is financed. <https://commonslibrary.parliament.uk/research-briefings/sn00724/#:~:text=Expenditure%20on%20the%20NHS%20has,established%20on%205th%20July%201948.&text=The%20average%20annual%20expenditure%20increase,the%20history%20of%20the%20NHS>. Accessed 10th August 2020
2. Weszl M, Rencz F, Brodsky V. Is the trend of increasing use of patient-reported outcome measures in medical device studies the sign of shift towards value-based purchasing in Europe?. *Eur J Health Econ.* 2019;20(Suppl 1):133-140. doi:10.1007/s10198-019-01070-1
3. U.S. Food and Drug Administration: Value and use of patient-reported outcomes (PROs) in assessing effects of medical devices. CDRH strategic priorities 2016–2017.

<https://www.fda.gov/files/about%20fda/published/Value-and-Use-of-Patient-Reported-Outcomes-%28PROs%29-in-Assessing-Effects-of-Medical-Devices.pdf> Accessed 10th August 2020

4. Lubkin V, Sloan S. Enucleation and psychic trauma. *Adv Ophthalmic Plast Reconstr Surg* 1990;8:259Y62.
5. McBain HB, Ezra DG, Rose GD, Newman SP. The Psychosocial impact of living with an ocular prosthesis. *Orbit* 2014; 33(1): 39-44.
6. Song JS, Oh J, Baek SH. A survey of satisfaction in an ophthalmic patients wearing ocular prosthesis. *Graefes Arch Clin Exp Ophthalmol* 2006;244(3):330–335.
7. Walshaw E, Zoltie T, Bartlett P, Gout T. Manufacture of a high definition ocular prosthesis. *British Journal of Oral and Maxillofacial Surgery*. 2018.
8. Carr T, Moss T, and Harris D. The DAS24: A short form of the Derriford Appearance Scale (DAS59) to measure individual responses to living with problems of appearance. *Br J Health Psych* 2005;10(2),285-298.
9. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. *Acta Psychiatr Scand* 1983;67:361–370.
10. Cano SJ, Klassen A, Pusic AL. The science behind quality-of life measurement: a primer for plastic surgeons. *Plast Reconstr Surg* 2009;123:98e–106e.
11. Kosowski TR, McCarthy C, Reavey PL, Scott AM, Wilkins EG, Cano SJ et al. A systematic review of patient-reported outcome measures after facial cosmetic surgery and/or nonsurgical facial rejuvenation. *Plast Reconstr Surg* 2009;123:1819–1827.
12. Klassen AF, Cano SJ and Pusic AL. A PROM for cosmetic facial procedures: developing the conceptual framework. *International Society for Quality of Life Research meeting abstracts*. The QLR Journal, 2009:A-68, Abstract 1614.
13. Klassen A, Cano SJ, Scott A, Snell L, Pusic AL. Measuring Patient-Reported Outcomes in Facial Aesthetic Patients: Development of the FACE-Q. *Facial Plast Surg* 2010;26:303–309.
14. Scientific Advisory Committee of the Medical Outcomes Trust. Assessing health status and quality-of-life instruments: attributes and review criteria. *Qual Life Res* 2002;11:193–205
15. Klassen AF, Cano SJ, Grotting JC, Baker SB, Carruthers J, Carruthers A et al. FACE-Q eye module for measuring patient-reported outcomes following cosmetic eye treatments. *JAMA Facial Plast Surg*. 2017;19(1):7-14.
16. Aggarwal H, Kumar P and Singh SV. Modified technique to improve fabrication and outcome of definitive orbital prosthesis. *Orbit*. 2016;35(2):66-8. doi: 10.3109/01676830.2015.1078379. Epub 2016 Feb 18.
17. Murthy R, Umesh M. Fabricating a custom made ocular prosthesis. *Indian J Ophthalmol*. 2015 Oct;63(10):807-8. doi: 10.4103/0301-4738.171536.
18. Patton, MQ. 1978. *Utilization-focused evaluation*. Beverly Hills, CA: Sage Publishers.

Figure Legends

Table 1. FACE-Q: Descriptive Analysis of the Mean and 95% Confidence Interval.

Table 2a-b. DAS24: Descriptive Analysis of the Mean and 95% Confidence Interval.

Table 3a-d. HADS: Descriptive Analysis of the Mean and 95% Confidence Interval.

Table 4. FACE-Q: Principal Component Analysis.

Figure 1. Patient Pathway. Flowchart describing patient flow through the new ocular prosthesis service⁴.

Figure 2. New Ocular Prostheses Appearance. Three cases demonstrating the new ocular prostheses with different iris colours provided by the service. The artificial eyes are as follows: top (patient's left eye with brown iris), middle (patient's right eye with green iris), bottom (patient's left eye with blue iris).

Table 1

FACE-Q	
Rasch Transformed	Mean (95%CI)
Expectations	61.8(51.8,71.9)
Appearance	37.4(13.1,61.7)
Social	54(38.4,69.6)
Satisfaction Outcome	63.7(47.5,80.0)
Satisfaction Appearance	53.6(39.7,67.4)
Psychological	54.7(32.6,76.9)
Adverse Eyes	36.6(27.5,45.7)
Satisfaction Eyes	59(38.7,79.3)

Table 2a-b

DAS24 Total Score (a-x)	
Mean (95% CI)	41.7(24.6,58.7)

DAS24 Individual Questions	
Question	Mean (95%CI)
A	2.28(1.6,2.9)
B	2.14(1.2,3.0)
C	1.28(0.3,2.2)
D	2.14(1.3,2.9)
E	1.85(0.7,2.9)
F	1.57(0.6,2.4)
G	1.85(1.0,2.6)
H	1.42(1.0,1.7)
I	2.71(1.7,3.6)
J	1.85(1.0,2.6)
K	2.00(1.2,2.7)
L	1.00(0.2,1.7)
M	2.14(1.1,3.1)
N	1.71(0.9,2.4)
O	0.85(0.1,1.5)

P	1.71(0.5,2.8)
Q	1.71(0.9,2.4)
R	1.00(0.03,1.9)
S	2.00(1.1,2.8)
T	2.00(1.2,2.7)
U	1.42(0.3,2.4)
V	1.71(0.8,2.5)
W	2.28(1.4,3.1)
X	1.00(0.03,1.9)

Table 3a-d

HADS Total Anxiety Score	
Mean (95%CI)	6.14(2.5,9.7)

HADS Individual Anxiety Questions	
Question	Mean (95% CI)
Tense	1.14(0.4,1.8)

Fright	0.85(0.02,1.6)
Worry	0.71(-0.04,1.4)
Relaxed	1.14(0.6,1.6)
Butterflies	1.00(0.2,1.7)
Restless	0.71(0.1,1.2)
Panic	0.57(0.03,1.1)

HADS Total Depression Score	
Mean (95%CI)	6.28(1.9,10.6)

HADS Individual Depression Questions	
Question	Mean (95% CI)
Enjoy	1.28(0.4,2.1)
Laugh	0.57(0.03,1.1)
Cheerful	0.57(0.03,1.1)
Slowed	1.28(0.3,2.2)
Appearance	1.00(0.1,1.8)

Things	0.85(0.1,1.5)
Enjoy	0.71(0.1,1.2)

Table 4

FACE-Q						
Variables	Principal Components					
	PC1	PC2	PC3	PC4	PC5	PC6
(1) Psychological	0.98*	-0.05	-0.12	-0.03	0.03	0.06
(2) Satisfaction_Eyes	0.96*	0.08	-0.05	0.17	0.10	0.07
(3) Adverse_Eyes	-0.90*	0.27	0.20	0.16	-0.07	0.17
(4) Satisfaction_Outcome	0.90*	0.22	0.25	0.15	0.22	-0.01
(5) Appearance	-0.87	0.25	0.30	0.23	0.09	-0.08
(6) Social	0.84	0.27	-0.05	0.36	-0.26	-0.05

(7) Satisfaction_Appearance	0.70	0.36	0.45	-0.038	-0.11	-0.00
(8) Expectations	-0.28	0.85	-0.39	-0.13	0.06	-0.01

Note. Extraction Method: Principal Component Analysis. 6 components were extracted.
Rotation Method: Oblimin with Kaiser Normalisation. Significant correlations were accounted when factor loading ($\alpha > 0.4$)

* Denotes excellent (≥ 0.9) internal consistency

Ophthalmology clinical assessment

Operation

Post-operative clinical review and assessment for suitability for prosthesis

Referral from external source, such as National Artificial Eye Service (NAEs)

Joint Prosthetic Clinic (approximately 6 weeks post operatively) – with orbital prosthesis, medical imaging and maxillofacial prosthetic technician.

Photography (1hr), mould taking and prosthesis manufacturing (3.5hr).

12 hours overnight setting of prosthesis

Joint Prosthetic Clinic – to evaluate artificial prosthesis fit and appearance.

